Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa

Arriola‐Villalobos, Pedro; Díaz-Valle, D.; Alejandre-Alba, Nicolás; López-Abad, C; Méndez-Fernández, R.; Benítez-del-Castillo, J.M.

doi:10.1038/sj.eye.6703100

Cited by 14 publications

(6 citation statements)

References 6 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No major infectious side-effects were reported in the cases listed above. However, one case report described bilateral candida chorioretinitis following etanercept treatment (48).…”

Section: Commentsmentioning

confidence: 98%

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Haslund¹,

Lee²,

Jemec³

2009

Acta Derm Venerol

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a common inflammatory skin disease. Medical treatment is often disappointing and in severe disease surgery remains the therapy of choice. Extensive surgery may be effective but also mutilating. Patients experience a significant reduction in quality of life and the need for new treatment modalities are urgent. In recent years patients with HS have been treated off-label with tumour necrosis factor-alpha (TNF-alpha) inhibitors with a varying degrees of effect. We performed a systematic review of papers retrieved from two databases (PubMed and Web of Science) using the follow-ing keywords: hidradenitis suppurativa, acne inversa, infliximab, etanercept, and adalimumab. A total of 34 publications were retrieved, describing treatment of 105 patients. Most cases report treatment with infliximab (52/105). A positive treatment outcome was reported in 90/105 cases, with only 7/105 non-responders and 8/105 patients experiencing side-effects. The side-effects were comparable to those seen in other TNF-alpha inhibitor studies. In the majority of cases the treatment was effective when given as a suppressive therapy, but 15/105 cases were described with long-term remission (>or= 3 months) after the end of therapy. In most publications follow-up was, however, insufficient to allow a systematic exploration of this. TNF-alpha inhibitors seem to be effective in the treatment of HS. However, several questions remain to be answered through specific studies. This review has also identified a need for more standardized reporting of the outcomes as well as randomized controlled trials in this disease.

show abstract

“…No major infectious side-effects were reported in the cases listed above. However, one case report described bilateral candida chorioretinitis following etanercept treatment (48).…”

Section: Commentsmentioning

confidence: 98%

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Haslund¹,

Lee²,

Jemec³

2009

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…In a series of cases [51][52][53] as well as open cohort studies [54][55][56][57][58][59] conducted on groups of 4 to 15 patients who received ETA in doses of 25 mg twice weekly or 50 mg once/twice weekly, promising results regarding the efficacy of the drug in HS therapy were obtained.…”

Section: Etanerceptmentioning

confidence: 99%

Biologics for Hidradenitis Suppurativa: An Update

et al. 2018

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatosis characterized by an occurrence of nodules, abscesses, sinus tracks and scarring. Its pathogenesis is multifactorial and still not fully understood, therefore, current systemic therapies still remain a serious challenge. Increased levels of several proinflammatory cytokines have been reported in patients suffering from HS, therefore biologics appear as a new approach to therapy for this condition. Adalimumab is the only one internationally registered agent and should be considered first after the conventional therapies appear insufficient. The efficacy and safety profile of some preparations, like infliximab and etanercept was confirmed so far in randomized trials, but there are some new biologics which are still being evaluated and require more rigorous examination.

show abstract

“…For eyelid surgery, we found a case of postoperative eyelid infection in a patient taking etanercept 69. Additional cases of tuberculosis, human herpesvirus 6, bilateral candida and toxoplasmic uveitis were identified which speak to the immunodeficient state in patients receiving etanercept therapy 70–73…”

Section: Resultsmentioning

confidence: 96%

Ocular side effects of antirheumatic medications: a qualitative review

et al. 2020

View full text Add to dashboard Cite

TopicThis paper reviews the ocular side effects of medications used in the treatment of rheumatological conditions.Clinical relevanceRheumatic diseases are inflammatory conditions that may affect the skin, blood vessels, joints, muscles and internal organs. Immunosuppressive agents are often used as treatment and while powerful, they carry side effects and toxicities that need careful monitoring. Ophthalmic complications have been reported with the use of antirheumatic medications; however, there is a lack of literature synthesising these reports. This paper addresses this gap and hopes to inform both rheumatologists and ophthalmologists as they work together on the management of patients with rheumatological conditions.MethodsPubMed literature search was conducted from November to September 2019 searching for ocular side effects with the use of 25 rheumatological drugs.ResultsA total of 111 papers were included in this review. Adverse side effects were divided into non-infectious and infectious causes. Traditional disease-modifying antirheumatic drugs (DMARDs) were associated with pruritus, irritation and dryness of the conjunctiva while biologic DMARDS showed reports of new-onset/recurrent uveitis and demyelinating conditions. Infectious side effects included episodes of cytomegalovirus retinitis, toxoplasmic chorioretinitis and endophthalmitis. Other serious side effects were encountered and included in this review.ConclusionThe goal of this paper is to inform healthcare providers about potential ocular side effects from rheumatological medications. Healthcare providers are encouraged to learn more about these ophthalmic complications and find relevance within their clinical practice.

show abstract

Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa

Cited by 14 publications

References 6 publications

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Biologics for Hidradenitis Suppurativa: An Update

Ocular side effects of antirheumatic medications: a qualitative review

Contact Info

Product

Resources

About